IceCure (ICCM) Q1 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from one of our analysts? Email [email protected]
IceCure Medical's (NASDAQ:ICCM) quarterly call reflected stable operating expenses and a nearly unchanged net loss compared to the same period in 2024, despite a slight decrease in revenue and gross margin compared to the same period in 2024. Ongoing FDA engagement was highlighted by the submission of a sizeable post-market study plan, with leadership involvement from the FDA's Center for Devices and Radiological Health, but no set decision timeline. Cash reserves increased after both a bridge loan from its largest shareholder and new share offerings, enhancing the company's liquidity.
Source Fool.com
